Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechin-containing extracts, many consumers of cardiovascular drugs assume these products as a "natural" and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that "more-is-better"
Overview of green tea interaction with cardiovascular drugs / J.P. Werba, S. Misaka, M.G. Giroli, S. Yamada, V. Cavalca, K. Kawabe, I. Squellerio, F. Laguzzi, S. Onoue, F. Veglia, V. Myasoedova, K. Takeuchi, E. Adachi, N. Inui, E. Tremoli, H. Watanabe. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1873-4286. - 21:9(2015), pp. 1213-1219.
|Titolo:||Overview of green tea interaction with cardiovascular drugs|
|Parole Chiave:||Green tea; herb-drug interaction; dietary-drug interaction; catechins; simvastatin; warfarin; nadolol; cardiovascular drugs|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||2015|
|Data ahead of print / Data di stampa:||13-ott-2014|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.2174/1381612820666141013135045|
|Appare nelle tipologie:||01 - Articolo su periodico|